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Abstract 20 
Type I interferon (IFN) signaling engenders an antiviral state that likely plays an 21 
important role in constraining HIV-1 transmission and contributes to defining 22 
subsequent AIDS pathogenesis. Type II IFN (IFNγ) also induces an antiviral state but is 23 
often primarily considered to be an immunomodulatory cytokine. We report that IFNγ 24 
stimulation can induce an antiviral state that can be both distinct from that of type I 25 
interferon, and can potently inhibit HIV-1 in primary CD4+ T cells and a number of 26 
human cell lines. Strikingly, we find that transmitted/founder (TF) HIV-1 viruses can 27 
resist a late block that is induced by type II IFN, and the use of chimeric IFNγ- 28 
sensitive/resistant viruses indicates that interferon-resistance maps to the env gene. 29 
Simultaneously, in vitro evolution also revealed that just a single amino acid substitution 30 
in envelope can confer substantial resistance to IFN-mediated inhibition. Thus, the env 31 
gene of transmitted HIV-1 confers resistance to a late block that is phenotypically 32 
distinct from those previously described to be resisted by env, and is therefore mediated 33 
by unknown IFNγ-stimulated factor(s) in human CD4+ T cells and cell lines. This 34 
important unidentified block could play a key role in constraining HIV-1 transmission. 35 
 36 
Importance 37 
The human immune system can hinder invading pathogens through interferon (IFN) 38 
signaling. One consequence of this signaling is that cells enter an 'antiviral state', 39 
increasing the levels of hundreds of defenses that can inhibit the replication and spread 40 
of viruses. The majority of HIV-1 infections result from a single virus particle (the 41 
transmitted/founder) that makes it past these defenses and colonizes the host. Thus, 42 
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the founder virus is hypothesized to be a relatively interferon-resistant entity. Here we 43 
show that certain HIV-1 envelope genes have the unanticipated ability to resist specific 44 
human defenses mediated by different types of interferons. Strikingly, the envelope 45 
gene from a founder HIV-1 virus is far better at evading these defenses than the 46 
corresponding gene from a common HIV-1 lab strain. Thus, these defenses could play a 47 
role in constraining the transmission of HIV-1, and may select for transmitted viruses 48 
that are resistant to this IFN-mediated inhibition. 49 
 50 
Introduction 51 
Humans have evolved to possess a diverse arsenal of antiretroviral defenses. 52 
Despite this, the human immune system is unable to eradicate an established human 53 
immunodeficiency virus (HIV) infection. Following infection, individuals mount vigorous 54 
immune responses targeting HIV-1 (1). While these responses are unable to clear 55 
systemic HIV-1 infection, the timing and magnitude of the innate and acquired immune 56 
responses still play a key role in shaping disease progression and pathogenesis. 57 
A major component of innate immunity is the interferon (IFN) system, which is 58 
comprised of a diverse family of related cytokines that for humans includes 17 type I 59 
IFNs (13 IFNα subtypes, as well as IFN β, κ, ε and ω), one type II IFN (IFNγ) and 4 type 60 
III IFNs (IFNλ1-4). Research into how IFNs inhibit retroviruses has largely focused on 61 
type I IFNs as type I/III IFNs are often perceived as the major antiviral IFNs, whereas 62 
IFNγ is frequently considered solely as an immunomodulatory player (2). To this end, it 63 
is now well established that type I IFNs inhibit infection and replication of HIV-1 and 64 
related primate lentiviruses both in vitro (3-12) and in vivo (13) (recently reviewed by 65 
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Doyle et al., (2)). Notably, HIV-1 infected individuals treated with IFNα experience 66 
significant, albeit transient, reductions in viral loads (13). Similarly, rhesus macaques 67 
administered IFNα can resist simian immunodeficiency virus (SIV) infection (14). In 68 
addition, transmitted HIV-1 is proposed to be relatively IFN-resistant (15, 16) (although 69 
this is not universally observed (17)). Despite this, IFNs are not always beneficial to the 70 
host, and repeated IFN administration in primate models (14), or persistent stimulation 71 
in chronically infected patients, is associated with poorer clinical outcome (18, 19). 72 
Thus, although IFN responses do not eradicate systemic HIV-1, there is great interest in 73 
understanding how IFNs might shape susceptibility to HIV-1 infection and subsequent 74 
progression to AIDS. 75 
Over the last decade, much of the attention paid to the ability of type I IFNs to 76 
inhibit HIV-1 has focused on restriction factors, including TRIM5/TRIMCyp (20, 21), 77 
APOBEC3s (22), Tetherin/BST2 (23) and SAMHD1 (24, 25). These interferon-78 
stimulated genes (ISGs) represent powerful barriers that primate lentiviruses must 79 
evade or overcome in order to thrive within human populations (26), and even 80 
successful viruses do not always completely escape inhibition by these factors (27). 81 
Alongside the restriction factors, a growing number of other ISGs have been identified 82 
as being capable of inhibiting HIV-1, but are not fully evaded or antagonized in natural 83 
settings. These ‘resistance factors’ include IFITMs (28-30), GBP5 (31) and Mx2/MxB 84 
(32, 33). Importantly, these known resistance factors, along with the established 85 
restriction factors, still cannot fully explain the IFN-mediated inhibition of HIV-1 observed 86 
in vitro (2). Thus, there is great interest in understanding the molecular details of how 87 
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IFNs might constrain HIV transmission, acute viral replication, pathogenesis or even the 88 
pandemic potential of geographically restricted HIVs (13-16, 30, 34, 35).  89 
Despite this predominant focus on type I IFNs and type I ISGs, reports in the last 90 
century demonstrated that IFNγ treatment can also confer substantial antiretroviral 91 
activity in vitro (5, 9, 36, 37). Recently, this concept has been revisited with the 92 
observations that some antiretroviral ISGs, such as GBP5 and IDO1, are most strongly 93 
upregulated by IFNγ (31, 38). Although the antiretroviral potential of IFNγ has been 94 
reported, and patients mount robust IFNγ responses following HIV-1 infection (1), the 95 
clinical significance of these observations is currently unclear.  96 
Here we show that IFNγ has anti-HIV-1 activity in primary CD4+ T cells and a 97 
number of common cell lines, and can induce strong early and late blocks to HIV-1 98 
replication. IFNγ can induce a divergent antiviral state from type I IFNs, and potent 99 
IFNγ-induced early block(s) to HIV-1 infection can be entirely independent of Mx2. 100 
Surprisingly, not all HIV viruses are equally susceptible to IFNγ-mediated inhibition, and 101 
certain HIV-1 and HIV-2 viruses can resist inhibition. Crucially, HIV-1 102 
transmitted/founder (TF) viruses are strikingly resistant to a late IFNγ-stimulated block. 103 
Using two independent approaches, we map IFN-resistance to the HIV-1 env gene. 104 
Notably, a single amino acid (aa) substitution in envelope conferred substantial 105 
resistance to IFN-mediated inhibition. Thus, the env gene from transmitted HIV-1 can 106 
resist unidentified IFN-induced factor(s) and this ability has been lost in multiple 107 
common lab strains. The potent inhibition observed here suggests that type II IFN may 108 
play an underappreciated role in limiting HIV-1 transmission and disease progression, in 109 
a fashion similar to type I IFNs. 110 
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 111 
Materials and Methods 112 
Cell lines 113 
 We assembled a panel of cell lines that are commonly used in HIV-1 research 114 
and/or were readily available from the UK National Institute of Biological Standards and 115 
Control (NIBSC). Jurkat, THP-1, HEK 293T, TE671 (RD or TE671/RD), and TZM-bl cell 116 
lines were a generous gift from Paul Bieniasz. MONOMAC6 cells were a generous gift 117 
from Mark Marsh and A549 cells were a generous gift from Ben Hale. The following cell 118 
lines were obtained from the UK NIBSC (repository reference indicated in parentheses): 119 
Molt 4 Clone 8 (ARP052), H9 (ARP001), HUT78 (ARP002), MOLT3 (ARP010), MOLT4 120 
(ARP011), U937 (ARP012), HL60 (ARP030), PM1 (ARP057), AA-2 (ARP054), KARPAS 121 
45 (ARP032) and U87 (U87.MG, ARP 043). Human suspension cell lines were 122 
maintained in RPMI supplemented with 9% FCS and gentamycin, with the exception of 123 
MONOMAC6 cells whose culture medium was also supplemented with NEAA and OPI. 124 
The remaining cell lines were cultured in DMEM supplemented with 9% FCS and 125 
gentamycin. All cell lines were tested for mycoplasma contamination, and the KARPAS 126 
45 cell line tested positive for mycoplasma at the end of this study and should be 127 
considered as mycoplasma positive throughout this study. The CCR5+ MT4-R5-LTR-128 
GFP indicator cells were described previously and contain a cassette in which hrGFP 129 
expression is driven by the HIV-1 LTR (38, 39). 130 
 PMA-treated THP-1 cells were seeded with 30 ng/ml of PMA in RPMI plus 9% 131 
FCS and gentamycin overnight, and washed the following morning (~16h later) to 132 
remove the PMA. 133 
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 134 
Primary Cells 135 
 As described previously (30), human primary CD4+ T cells were obtained from 136 
peripheral blood mononuclear cells (PBMCs) from healthy human donors. Ethical 137 
approval for primary cell work was granted by King’s College London Infectious Disease 138 
BioBank Local Research Ethics Committee (under the authority of the Southampton and 139 
South West Hampshire Research Ethics Committee—approval REC09/H0504/39), 140 
approval number SN-1/6/7/9. In brief, PBMCs were isolated by density gradient 141 
centrifugation through Lymphoprep (Axis-Shield) and CD4+ T cells obtained by negative 142 
selection using the Dynabeads Untouched Human CD4 T Cells kit (Life Technologies) 143 
using the manufacturer’s instructions. Flow cytometry for CD4 was used to assess the 144 
purity of the isolated cell population, which was reproducibly >95%. Cells were cultured 145 
with RPMI supplemented with 10% FCS, 20μg/ml gentamycin, and 30 U/ml recombinant 146 
IL-2 (PeproTech), and were then activated within 48 hours using Dynabeads Human T-147 
Activator CD3/CD28 beads (CD3/CD28 Dynabeads, Invitrogen) using the 148 
manufacturer’s instructions. Cells were typically resuspended in flasks with the 149 
CD3/CD28 Dynabeads at 1:5 bead:cell ratio (cells at 1x106 cells/ml). Cells were washed 150 
and resuspended in fresh RPMI-IL-2 supplemented media prior to infection or post-151 
activation analysis. Where indicated, cells were treated with IFNγ (1000 U/ml, human 152 
interferon gamma, Thermo Fisher, PHC4031) for 24 hours before virus infection.  153 
 154 
Primate lentiviruses 155 
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 Lentivirus stocks (Table 1) were all generated through transient transfection of 156 
HEK 293T cells in the presence/absence of pCMV-VSV-G using polyethylenimine (PEI). 157 
The following proviral clones were used: pNL4-3 (M19921.2) (40); pROD10 (KY272752) 158 
(41); pJK7312A (L36874) (42); pCMO2.5 (AY623602.1) (43); as well as replication 159 
competent GFP-encoding pNHG (JQ585717) (44, 45); and the following HIV-1 strains 160 
that were obtained from the NIH AIDS reagents program (catalog numbers indicated in 161 
parentheses): pNL(AD8) (11346), pYK-JRCSF (JRCSF, 2708), p89.6 (3552), 162 
pZM249M-1 (12260) and a panel of full length transmitted/founder (TF) HIV-1 infectious 163 
molecular clones (11919). In addition to chimeric/mutant proviral clones, env minus 164 
GFP-encoding NHGΔenv-GFP (44, 46) and pHIV-2RODΔenv-GFP (33) were also used. 165 
In all cases, supernatants were harvested at ~48 h post-transfection and clarified using 166 
a 0.45 μm filter. 167 
 168 
Vesicular Stomatitis Virus (VSV) 169 
 VSV-GFP (Indiana serotype) competent to undergo a single round of infection but 170 
not encoding the VSV-G envelope (rVSV-ΔG-GFP decorated with VSV-G expressed in 171 
trans) was used (47). Virus stocks were generated through transfection of HEK293T 172 
using PEI (PolySciences) with 2μg of VSV-G plasmid. The following day, the cells were 173 
infected with rVSV-ΔG-GFP at MOI 1. Progeny VLP stocks were harvested at 24 hours 174 
postinfection and clarified using a 0.45 μm filter. 175 
 176 
Plasmid construction of chimeric/mutant viruses 177 
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 Chimeric proviral molecular clones between pNL4-3 (M19921.2) and pCH040 178 
(NIH AIDS Reagent Program 11919) were constructed first by introducing an MluI 179 
restriction site outside of the proviral sequence in pNL4-3 (in the 3' host genomic 180 
sequence) by inserting the following complementary oligonucleotides inside of the 181 
unique NcoI site (5'-CAT GTA CGC GTA AGC TTA-3' & 5'-CAT GTA AGC TTA CGC 182 
GTA-3'). The resulting pNL4-3ΔNcoI+MluI was used as a backbone to receive BssHII-183 
ApaI (pNL-040-BA), ApaI-EcoRI (pNL-040-AE), EcoRI-BlpI (pNL-040-EB) or BlpI-MluI 184 
(pNL-040-BM) fragments from pCH040. 185 
 To generate pNL(CH040) and pNL(CH040BamHI), overlap extension PCR was 186 
used to weave together the amplified sequence of pNL4-3 between the unique EcoRI 187 
site and the start codon of env (5'-GAT ACT TGG GCA GGA GTG GAA GCC ATA ATA 188 
AGA ATT CTG C-3' & 5'-CCT GAT CCC CAT CAC TCT CAT TGC CAC TGT CTT CTG 189 
CTC TTT CTA TTA G-3') with the PCR amplified region of pCH040 between the env 190 
start codon and the BlpI site (5'-GAG CAG AAG ACA GTG GCA ATG AGA GTG ATG 191 
GGG ATC AGG AAG AAT TAT C-3' & 5'-TAT TGC TAC TTG TGA TTG CTC CAT G-3') 192 
or the amplified region of pCH040 between the start codon and the BamHI site in the 193 
NL4-3 env (5'-GAG CAG AAG ACA GTG GCA ATG AGA GTG ATG GGG ATC AGG 194 
AAG AAT TAT C-3' & 5'-GAG AGA GGA TCC GTT CAC TAA TGG ATC GGA TCT G-195 
3'). CH040 has no BamHI site in env and this site was specified in the oligonucleotide 196 
sequence (italicized). PCRs were completed using PfuTurbo (Agilent) and inserted into 197 
pNL4-3ΔNcoI+MluI using EcoRI and BlpI for pNL(CH040), and EcoRI and BamHI for 198 
pNL(CH040BamHI).  199 
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 To generate the T192M mutant virus, overlap extension PCR was used to weave 200 
a region of pNHG (JQ585717) amplified using oligonucleotides 5'-GAT ACT TGG GCA 201 
GGA GTG GAA GCC ATA ATA AGA ATT CTG C-3' & 5'-GTA ATG ACT GAG GTG 202 
TTA CAA CTT GTC AAC ATA TAG CTG GTA GTA TCA TTA TCT ATT GG-3' together 203 
with a region of pNHG amplified using oligonucleotides 5'-CCA ATA GAT AAT GAT 204 
ACT ACC AGC TAT ATG TTG ACA AGT TGT AAC ACC TCA GTC ATT AC-3' & 5'-205 
AGA GAG GCG GCC GCT TAT AGC AAA ATC CTT TCC AAG CCC-3' (italicized 206 
nucleotides specify the C6795T/T192M mutation). To generate the T192R mutant virus, 207 
overlap extension PCR was also used to weave a region of pNHG (JQ585717) 208 
amplified using oligonucleotides 5'-GAT ACT TGG GCA GGA GTG GAA GCC ATA ATA 209 
AGA ATT CTG C-3' & 5'-GTA ATG ACT GAG GTG TTA CAA CTT GTC AAC CTA TAG 210 
CTG GTA GTA TCA TTA TCT ATT GG-3' together with a region of pNHG amplified 211 
using oligonucleotides 5'-CCA ATA GAT AAT GAT ACT ACC AGC TAT AGG TTG ACA 212 
AGT TGT AAC ACC TCA GTC ATT AC-3' & 5'-AGA GAG GCG GCC GCT TAT AGC 213 
AAA ATC CTT TCC AAG CCC-3' (italicized nucleotides specify the C6795G/T192R 214 
mutation). The PCRs were completed using PfuTurbo (Agilent) and inserted into pNHG 215 
using EcoRI and BamHI. 216 
 To generate CH040 and NL4-3 env chimeras, overlap extension PCR was used 217 
to weave together a fragment of NL(CH040) amplified using 5'-GAT ACT TGG GCA 218 
GGA GTG GAA GCC ATA ATA AGA ATT CTG C-3' paired with either 5'-TTG GGG 219 
TCT GTG GGT ACA CAG GCG TGT GTG GCC CAA ACA TTA TGT G-3' (NL(CH0401-220 
83)), 5'-TTG TGC TGA TAT TGA AAG AGC AGT TTT TTA CTT CTC CCT TCT CCA 221 
TC-3' (NL(CH0401-157)), 5'-TGA GTT GAT ACT ACT GGC CTA ATT CCA TGT GTA 222 
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 11
CAT TGT ACT GTG-3' (NL(CH0401-264)), 5'-GTT GAA TTA CAG TAG AAA AAT TCC 223 
CCT CCG CAA TTG AAA CTG TAC-3' (NL(CH0401-381)), 5'-CTC TTG TTA ATA GCA 224 
GCC CAG TAA TGT TTG ATG AGC ATC TAA TTT TTC C-3'  (NL(CH0401-448)) or 5'-225 
ATT CCC ACT GCT CTT TTT TCC CTC TGC ACC ACT CTC CTC TTT GCC-3' 226 
(NL(CH0401-502)) with a fragment of pNL4-3 amplified using 5'-AGA GAG GCG GCC 227 
GCT TAT AGC AAA ATC CTT TCC AAG CCC -3' paired with either 5'-ATG TTT GGG 228 
CCA CAC ACG CCT GTG TAC CCA CAG ACC CCA ACC CAC-3' (NL(CH0401-83)), 5'-229 
AAG GGA GAA GTA AAA AAC TGC TCT TTC AAT ATC AGC ACA AGC ATA AG-3' 230 
(NL(CH0401-157)), 5'-TAC AAT GTA CAC ATG GAA TTA GGC CAG TAG TAT CAA 231 
CTC AAC TGC-3' (NL(CH0401-264)), 5'-GTT TCA ATT GCG GAG GGG AAT TTT TCT 232 
ACT GTA ATT CAA CAC AAC-3'  (NL(CH0401-381)), 5'-AGA TGC TCA TCA AAC ATT 233 
ACT GGG CTG CTA TTA ACA AGA GAT GGT GG-3'  (NL(CH0401-448)) or 5'-AGA GGA 234 
GAG TGG TGC AGA GGG AAA AAA GAG CAG TGG GAA TAG GAG -3' (NL(CH0401-235 
502)). PCRs were completed using PfuTurbo (Agilent) and inserted into pNL4-236 
3ΔNcoI+MluI using EcoRI and BamHI. 237 
 238 
Western blot analyses 239 
 Cell lysates or VLPs were resolved using 4-12% acrylamide gels, transferred onto 240 
nitrocellulose membranes and probed with either: anti-actin (JLA20 hybridoma, provided 241 
by the Developmental Studies Hybridoma Bank at the University of Iowa); anti-Mx2 (SC-242 
47197, Santa Cruz Biotechnology Inc.); anti-IDO1 (Abcam, ab55305); anti-phospho-243 
STAT1 (Tyr701) (Cell Signaling Technology, 9171); or anti-CA (183-H12-5C 244 
hybridoma), anti-gp41 (Chessie 8 hybridoma) or anti-gp120 (Chessie 13-39.1 245 
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hybridoma) from the NIH AIDS reagent program (catalog numbers 1513, 526, 990 246 
respectively). Membranes were then probed with fluorescently labeled goat/donkey 247 
secondary antibodies (Thermo Scientific) prior to scanning with a LI-COR Odyssey 248 
scanner.  Band intensities were quantified using Image Studio software (LI-COR). 249 
 250 
Cell line authentication 251 
  The identities of THP-1, MT4, A549, TE671 and U87 cells (which all exhibited 252 
inhibitory IFNγ phenotypes) were confirmed using STR analysis carried out by the DDC 253 
(DNA Diagnostics Centre, UK) and analyzed using the DSMZ online STR analysis tool. 254 
Although we have used the term TE671 throughout this manuscript, the ATCC STR 255 
analysis was unable to substantially distinguish between TE671 (ATCC® HTB-139) and 256 
RD (ATCC® CCL-136). Our TE671 cells were identified as the rhabdomyosarcoma cell 257 
line RD by the DDC/DSMZ. The TE671 cell line is likely derived from RD cells and 258 
ATCC® HTB-139 has been discontinued for this reason (48). We opted to use the term 259 
TE671 as it is common in the field, however TE671/RD or RD more accurately reflects 260 
the lineage of this line. The identity of TZM-bl cells was validated using a TZM assay.  261 
 262 
Virus Titrations 263 
 Virus titrations were carried out as described previously (38, 39, 45, 49, 50). 264 
Briefly, target cells were infected with a titrated challenge of serially diluted virus-265 
containing supernatant. Suspension cell lines were treated with polyanionic dextran 266 
sulfate ~18 hours postinfection to limit infection to a single cycle. At 48 hours 267 
postinfection, the level of infection was determined using flow cytometry (for either GFP-268 
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encoding viruses or MT4-R5-LTR-GFP infected cells) or TZM-bl infected foci were 269 
enumerated using an AID VIRUSpot reader. In all cases, the value plotted is the mean 270 
of at least triplicate (n=3 to 5) estimations of the titer extrapolated from different doses 271 
within the linear range (error bars represent the standard error of the mean). A typical 272 
result from at least two independent experiments is shown.  273 
 274 
Infectious Yield assays 275 
 The infectious yield assays were carried out essentially as described previously 276 
(38). Briefly, cells were seeded in 6-well plates and treated, as indicated, with IFNγ (Life 277 
Technologies, PHC4031) or pegylated IFNα2 (ViraferonPeg, Schering-Plough) in the 278 
absence or presence of additional L-tryptophan (50 μg/ml) or 1-methyl-L-tryptophan 279 
(100 μg/ml), as indicated. Adherent cell lines were seeded an additional day prior to IFN 280 
treatment. The unit dose of IFNγ was determined using the most conservative estimate 281 
given by the manufacturer (2x106 units/mg). At 24h after IFNγ or IFNα2 treatment, cells 282 
were infected with the indicated virus at an MOI of 0.5, or at an MOI <0.5 for viruses in 283 
which an MOI of 0.5 was unachievable due to low infectious titers (for non-VSV-G 284 
pseudotyped JRCSF, THRO, CH040, and CH077, in which case 1800 μl of virus-285 
containing supernatant was used) for 6h, after which the inoculum was removed by 286 
washing the cells in PBS. At 46-48h post-infection cells were lysed in SDS sample 287 
buffer and the virus-containing supernatant was harvested, filtered and titrated onto 288 
TZM-bl cells or MT4 cells as described above, or pelletable material was isolated for 289 
western blotting by centrifugation through a 20% sucrose cushion. 290 
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 The 46-48 h time point for harvesting was based upon a recent analysis of the 291 
replication kinetics of HIV-1 in MT4 cells (51). MT4 cells are the most susceptible and 292 
permissive target for HIV-1 NHG replication we are aware of (Figure 2A). Holmes et al. 293 
(51) estimated a typical MT4 cell produces virus 40-46 hours after infection and that 294 
progeny virions are barely detectable at 24 hours. Thus 46-48 h is a time point where 295 
abundant progeny virions have been produced from the first round of infection but 296 
where progeny virions from the second round of infection have not yet had time to 297 
accumulate (51). Harvesting at earlier time points (such as 40h) that could effectively 298 
exclude progeny resulting from the 2nd round of infection, greatly reduced the infectious 299 
titer (51). 300 
 301 
Primary Cell Assays 302 
 Where indicated, cells were treated with 1000 U/ml IFNγ (Thermo Fisher, 303 
PHC4031) for 24 h before virus infection. In all cases, 2×105 activated CD4+ T cells 304 
were infected at an MOI of 0.05 to 0.1 as specified (infectious titer determined via TZM-305 
bl assay). At 8-12 hours postinfection, media was replaced. Supernatants were 306 
harvested when indicated for up to 17 days post infection and infectious viral release at 307 
each time point was determined by infecting HeLa-TZM-bl indicator cells. At 48 hours 308 
post TZM-bl infection, virus release was assayed by measuring chemiluminescent β-309 
galactosidase activity using the Tropix Galacto-Star system (Applied Biosystems) 310 
according to the manufacturer’s instructions. 311 
 312 
HIV-1 in vitro evolution, DNA extraction, PCR and sequencing 313 
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 MT4 cells pretreated (24h with 1000 U/ml) or untreated with IFNγ were infected 314 
with HIV-1 (NHG, JQ585717) and the level of infection was monitored every 24 h using 315 
flow cytometry as described previously (39, 45). At the indicated time points, the IFNγ-316 
treated virus containing supernatant was clarified using a 0.45 μm filter and used to 317 
infect fresh cultures pretreated or not with IFNγ. Following passage 5, genomic DNA, 318 
laden with proviral insertions, was extracted using a DNeasy kit (Qiagen) and 6 319 
segments of NHG proviral DNA encompassing all coding regions were PCR amplified 320 
using GoTaq® polymerase (Promega) and the following primer pairs: 5'-GCG CCC GAA 321 
CAG GGA CTT GAA AGC G-3' & 5'-GGT GGG GCT GTT GGC TCT GGT CTG C-3', 5'-322 
TGA AAG ATT GTA CTG AGA GAC AGG C-3' & 5'-TTT CAC ATC ATT AGT GTG 323 
GGC ACC C-3', 5'-CAG AAG CAG GGG CAA GGC CAA TGG AC-3' & 5'-ACT TGC 324 
CAC ACA ATC ATC ACC TGC C-3', 5'-AAA GCT CCT CTG GAA AGG TGA AGG G-3' 325 
& 5'-ATT TAC CAA TAC TAC TTC TTG TGG G-3', 5'-GAT GCT AAA GCA TAT GAT 326 
ACA GAG G-3' & 5'-CAG ATG CTG TTG CGC CTC AAT AGC C-3', 5'-CGT CAA TGA 327 
CGC TGA CGG TAC AGG C-3' & 5'-TAA GAT CTA CAG CTC ATG AGT TGG C-3'. 328 
The amplicons were subsequently sequenced directly using Sanger sequencing 329 
(Eurofins Genomics). 330 
 331 
Analysis of HIV-1 transcription by qRT-PCR 332 
 MT4 or MT4-R5-LTR-GFP cells pretreated (24h with 1000 U/ml) or untreated with 333 
IFNγ were infected with HIV-1.  Cells were harvested using TRIzol reagent (Invitrogen) 334 
at 24 hours postinfection and RNA was isolated through a hybrid TRIzol and RNeasy 335 
(Qiagen) protocol (including an on-column DNase treatment).  PCR template cDNA was 336 
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generated using superscript III (Invitrogen) primed using random hexamers in 337 
accordance with the manufacturer's instructions.  The gag RNA copy number was 338 
determined using primers and probes described previously (52) that amplify a 339 
conserved region of HIV-1 gag compared with standards of serially diluted pNHG 340 
plasmid DNA.  To specifically measure transcribed RNA, for each condition, duplicate 341 
samples (where infection was blocked using dextran sulfate) were also analyzed (to 342 
enumerate the 'input' cell associated viral RNA).  To quantify transcribed RNA, the input 343 
vRNA was subtracted from the total number of gag RNA copies in infected cells.  344 
Values represent the mean of duplicate qPCR determinations of at least three replicate 345 
infections (error bars ± SEM, n=3).   346 
 347 
Analysis of env variants 348 
To determine the frequency of each amino acid at position 192 in HIV-1 env, the Los 349 
Alamos National Database (http://www.hiv.lanl.gov/) was used to download all env gene 350 
sequences available. Only one sequence was selected per patient, and 5000 351 
sequences were selected at random to determine the frequency of different amino acids 352 
at envelope position 192. 353 
 354 
Results 355 
IFNγ and IFNα induce divergent antiviral states in THP-1 cells 356 
Our recent demonstration of the anti-HIV-1 activity of IDO1 (38) led us to further 357 
consider the IFNγ-induced antiviral state. We initially examined THP-1 cells, which 358 
exhibit a strong IFN-induced block to HIV-1 infection (32). To confirm the induction of an 359 
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antiviral state, THP-1 cells were pretreated with IFNα2 or IFNγ for 24 hours before 360 
challenge with a single cycle VSV-GFP reporter virus. IFNα2 and IFNγ both potently 361 
inhibited VSV infection, although the inhibition displayed by IFNα2 against VSV was 362 
greater (Figure 1A). In parallel, we observed that IFNα2 and IFNγ conferred similar 363 
levels of protection (~10-fold) from a single cycle of VSV-G pseudotyped HIV-1 infection 364 
(Figure 1B). Finally, we considered the ability of a proviral clone of HIV-1 (NHG, a 365 
chimera of NL4-3 and HXB that encodes GFP in place of nef), to infect THP-1 cells 366 
stimulated with IFNα2 or IFNγ. Strikingly, whilst IFNγ conferred ~10-fold protection from 367 
HIV-1 infection in a single cycle, IFNα2 did not induce protection (Figure 1C). Thus, 368 
IFNα2 induced more potent anti-VSV activity whilst IFNγ conferred stronger anti-HIV-1 369 
activity in THP-1 cells. Together, these data demonstrate that IFNγ and IFNα can 370 
induce phenotypically divergent antiviral states that inhibit distinct spectra of viruses. 371 
Mx2 is known to mediate an early block to HIV-1 infection (32, 33). Mx2 372 
expression was potently upregulated in THP-1 cells stimulated with IFNα2 (Figure 1D), 373 
whereas IFNγ did not induce Mx2 expression. Importantly, the robust upregulation of 374 
Mx2 induced by IFNα2 in THP-1 cells did not inhibit HIV-1 (Figure 1C). Thus IFNγ can 375 
confer potent early protection against HIV-1 infection that is independent of Mx2. 376 
Considerable variation in the potency of anti-HIV-1 activity conferred by type I 377 
IFNs has been reported (53). Thus, we also considered the ability of IFNα14, which has 378 
potent anti-HIV-1 activity (53), alongside IFNα2 and IFNγ, to induce protection from HIV-379 
1 infection in THP-1 cells. Notably, only IFNγ induced substantial protection in a single 380 
cycle of HIV-1 infection (Figure 1E) in THP-1 cells.  381 
 382 
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IFNγ-induced blocks in primary cells and human cell lines 383 
 The divergent IFNγ-induced antiviral state in THP-1 cells led us to examine 384 
whether IFNγ also inhibited HIV-1 replication in primary cells. IFNγ treatment potently 385 
inhibited HIV-1 replication in CD4+ T cells suggesting this inhibition may be relevant in 386 
vivo (Figure 1F,G). Still, it is not clear whether this IFNγ-mediated inhibition occurs 387 
directly or indirectly, as it is possible that a minority of contaminating cells (such as 388 
monocytes or dendritic cells) could respond to IFNγ by secreting proinflammatory 389 
cytokines that induce an antiviral state in neighboring CD4+ T cells. Nevertheless, the 390 
strength of the inhibitory phenotype warranted further investigation. Since the 391 
mechanistic basis of IFN inhibition is typically dissected using common cell lines (32, 392 
33) and these cultures are more uniform, we used a panel of human cell lines to 393 
examine the capacity of IFNγ to either protect cells from HIV-1 infection or to inhibit the 394 
production of infectious progeny. We opted to treat our panel of cell lines with 1000 395 
units/ml of IFNγ (a relatively high dose) to ensure that we did not overlook cell lines 396 
exhibiting inhibitory phenotypes. 397 
 As we were interested in factors that specifically target HIV-1, we compared the 398 
ability of IFNγ treatment to inhibit HIV-1 and HIV-2, either early (Figure 2) or late (Figure 399 
3) in the viral lifecycle. Because not all of our cell lines could be efficiently infected with 400 
HIV-1 (NHG, Figure 2A) and few were efficiently infected with HIV-2 (ROD10), we also 401 
utilized VSV-G pseudotyped reporter viruses (Figure 2B,C). For the early (or incoming) 402 
inhibition highlighted in Figure 2, all assays were limited to a single cycle through the 403 
use of either envelope defective proviral clones or the addition of dextran sulfate 404 
following infection. Although modest protection from incoming infection (i.e. an early 405 
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block) was observed in some cell lines (≤5-fold), predominantly fibroblasts, only IFNγ-406 
stimulated THP-1 cells were substantially protected from HIV-1 and HIV-2 infection 407 
(~10-fold). Strikingly, PMA-treatment of THP-1 cells greatly enhanced (>1000-fold) this 408 
early block (Figure 2), with the levels of infection being too low for us to accurately 409 
enumerate following IFNγ treatment. Nevertheless, IFNγ-induced protection from 410 
infection appears unusual in human cell lines and is equally effective against HIV-1 and 411 
HIV-2 (Figure 2). In general, the rarity of IFNγ-induced early blocks to HIV infection 412 
makes it difficult to assess whether HIV-2 might be more sensitive than HIV-1 to IFNγ-413 
stimulated defenses, as is the case for IFNα (34).  414 
 Type I IFNs are known to induce both early (10) and late blocks to HIV-1 415 
replication (6). Similarly, single ISGs can also confer either early (20) or late blocks to 416 
HIV-1 replication (54). Therefore, we also considered the ability of IFNγ to inhibit later 417 
stages of the HIV-1 lifecycle. To do this, virus-containing supernatants were harvested 418 
at 46-48 hours postinfection, as nascent virions from the first round of infection were 419 
abundant in the supernatant at this time, but progeny virions from subsequent rounds of 420 
infection had not yet accumulated (51). This allowed us to measure the yield of 421 
infectious HIV-1 or HIV-2 resulting from ~1 round of infection (MOI 0.5, determined 422 
using data from Figure 2). 423 
 Unlike most cell lines, a substantial IFNγ-mediated reduction in infectious HIV-1 424 
yield was observed in MT4, THP-1, A549, TE671 (RD), TZM-bl and U87 cells (Figure 425 
3A). HIV-1 production from IFNγ-treated THP-1 cells was reduced by an almost 426 
identical magnitude (~10-fold) to the early block to infection observed in these cells 427 
(Figure 1C, 2A, 3A). Thus, the diminished titre of HIV-1 produced by these cells is likely 428 
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caused by the early/incoming block (Figure 1C,E and Figure 2A) rather than a reduced 429 
capacity for HIV-1 replication (a late/outgoing/production block).  Therefore, in THP-1 430 
cells, IFNγ induces inhibition early (but not late) in the HIV-1 lifecycle.  In contrast, IFNγ-431 
treated MT4, TE671, A549, TZM-bl and U87 cells potently inhibited (~10-800-fold) the 432 
production of infectious HIV-1 (Figure 3A), even when weak early blocks in these cells 433 
were overcome by increasing the initial inoculum (in direct proportion to the incoming 434 
block, purple bars in Figure 3A). Although the IFNγ receptor is expressed on nearly all 435 
cell types (reviewed in (55)), signaling responses can vary enormously (56). Thus, we 436 
examined the levels of activated STAT1 (phosphorylated at residue 701) in our panel of 437 
cell lines.  Nearly all cell lines responded robustly to IFNγ treatment, although KARPAS 438 
45, PM1 and SUPT1 responded poorly, providing a likely explanation for the lack of 439 
IFNγ-mediated inhibition of HIV-1 in these cells. Intriguingly, SUPT1 cells reproducibly 440 
exhibited STAT1 phosphorylation in the absence of cytokine treatment. More 441 
importantly however, many of the cell lines that responded robustly to IFNγ treatment 442 
did not inhibit HIV-1 replication.  Thus, the factor(s) responsible for IFNγ-stimulated HIV-443 
1 inhibition in select cell lines are likely not induced or not competent to inhibit HIV-1 in 444 
multiple other cell lines.   445 
 Remarkably, the stage of the viral lifecycle inhibited by IFNγ was superficially 446 
similar in all the cell lines exhibiting late blocks. Viral Gag and capsid (CA) expression 447 
were reduced in infected cells and there was a concomitant reduction in the yield of 448 
pelletable CA protein in the supernatant (Figure 3B). Thus, the diminished infectious 449 
yield caused by IFNγ is predominantly manifested as a reduction in viral gene 450 
expression and a paucity of progeny virions rather than the retention or inactivation of 451 
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abundant nascent viral particles. Strikingly, the yield of infectious HIV-1 was markedly 452 
reduced in IFNγ-treated MT4 cells (>500-fold), whereas HIV-2 largely escaped this 453 
inhibition (Figure 3C). The specificity of this block was especially apparent when the 454 
magnitudes of HIV-1 and HIV-2 inhibition were compared for all the tested cell lines 455 
(Figure 4A), as the late block to HIV-1 replication in MT4 cells appears as an outlier 456 
(although HIV-1-specific inhibition was also apparent in U87 cells to a lesser extent).  457 
 458 
The IFNγ-induced late block to HIV-1 replication in MT4 cells is independent of 459 
IDO1 and viral entry route 460 
 The large magnitude and specific nature of the late block in MT4 cells led us to 461 
consider this phenotype in more depth. The late block in MT4 cells was dose 462 
dependent, with 10 U/ml of IFNγ sufficient to block HIV-1 by ~100-fold, and IFNγ 463 
concentrations ≥10U/ml suppressing both viral protein expression and the genesis of 464 
progeny virions (Figure 4B,C). 465 
Because HIV-1 (NHG) was inhibited in IFNγ-treated MT4 cells whilst HIV-2 (VSV-466 
G pseudotyped ROD10) was largely resistant (Figure 3), we considered whether 467 
apparent resistance to late inhibition could be conferred by the envelope or entry 468 
pathway used for initial infection. Thus, we examined whether pseudotyped HIV-1 (NHG 469 
and NL4-3) was able to replicate in IFNγ-treated MT4 cells. IFNγ-stimulation potently 470 
blocked the replication of HIV-1, using a range of multiplicities of infection, even when 471 
the inoculum was pseudotyped with VSV-G (Figure 4D). Due to the coreceptor tropism 472 
of HIV-2 ROD10 and 7312A strains, we could only efficiently infect MT4 cells with 473 
pseudotyped HIV-2. However, in contrast to HIV-1, both the HIV-2 strains we tested 474 
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were strikingly resistant to IFNγ-mediated inhibition (Figure 4E). Thus, using a VSV-G 475 
envelope for initial infection does not circumvent the late block in MT4 cells and at least 476 
two HIV-2 strains were largely resistant to this inhibition. 477 
 We previously reported that IFNγ-induced IDO1 expression inhibits HIV-1 478 
replication through tryptophan depletion (38). Although the late block in MT4 cells 479 
appears superficially similar to that induced by IDO1, IDO1 expression was not induced 480 
in IFNγ-treated MT4 cells (Figure 4F), and inhibition of IDO1 (via 1-methyl-L-tryptophan) 481 
or exogenous L-tryptophan did not reverse the inhibition of HIV-1 in MT4 cells, unlike 482 
A549 cells (Figure 4G). Thus, the late IFNγ-induced block in MT4 cells is entirely 483 
independent of IDO1. 484 
 485 
Multiple HIV-1 strains are immune to the IFNγ-induced late block in MT4 cells 486 
 To consider if other HIV-1 strains were also sensitive to this late block in MT4 487 
cells, we examined divergent HIV-1 viruses, including multiple transmitted/founder (TF) 488 
clones. Because the majority of HIV-1 viruses, including the TF viruses, infect CD4+ 489 
CCR5+ T cells (57) we used clonal MT4 cells modified to express CCR5. In addition, 490 
these cells were further modified to express hrGFP in response to Tat expression, 491 
allowing the levels of HIV-1 infection to be quantified (39). IFNγ treatment conferred 492 
similar, but modest protection from incoming infection for all HIV-1 viruses in these cells 493 
(Figure 5A,D). In contrast, when HIV-1 production was analyzed, substantial variation in 494 
IFNγ-sensitivity was observed in these cells. Multiple group M HIV-1 viruses (NL4-3, 495 
NHG, NL(AD8) and 89.6) were potently blocked, and Group O HIV-1 (CMO2.5) was 496 
also inhibited (to a lesser extent). In contrast, JRCSF and all the TF viruses we tested 497 
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were largely resistant to IFNγ-mediated inhibition (Figure 5B,E). Indeed, for TF viruses, 498 
the magnitude of inhibition of infectious HIV-1 production was similar to the relatively 499 
small reduction in susceptibility to infection, suggesting that these viruses are almost 500 
entirely resistant to the late block in MT4 cells (Figure 5C,F). We thus conclude that the 501 
late block to HIV-1 replication in MT4 cells is highly specific and efficiently 502 
evaded/antagonized by TF viruses and might therefore recapitulate a block that TF 503 
viruses have been selected to overcome during natural transmission (15, 16). 504 
  505 
Envelope determines transmitted/founder virus resistance to the IFNγ-induced 506 
late block 507 
 In order to map the determinant(s) that confer resistance to IFNγ-mediated 508 
inhibition in MT4 cells, we made a series of chimeric viruses between NL4-3 (sensitive 509 
to inhibition) and the TF CH040 (relatively resistant to inhibition). These chimeras were 510 
constructed using unique restriction sites in the NL4-3 proviral clone and are 511 
represented in Figure 6A. Unfortunately, one of the clones, chimera NL-040-BA, which 512 
contained the majority of gag from CH040, was reproducibly severely attenuated and 513 
we were unable to assess the IFNγ-sensitivity of this virus. Notably, IFNγ-resistance 514 
mapped to the env gene, and chimera NL(CH040BamHI), which contains the majority of 515 
the TF CH040 envelope, was almost completely resistant to the IFNγ-induced late block 516 
to HIV-1 replication in MT4 cells and produced abundant nascent infectious particles 517 
despite IFNγ treatment (Figure 6A-E).  Furthermore, analysis of phosphorylated STAT1 518 
in cell lysates indicated that envelope-mediated IFNγ-resistance occurred downstream 519 
of STAT1 phosphorylation (Figure 6E). 520 
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  Subsequent analysis of HIV-1 transcription indicated that IFNγ treatment 521 
reduced HIV-1 transcription by ~3-fold, a magnitude similar to the weak early block 522 
observed in MT4 cells (Figures 6B, 7A). Moreover, NL4-3 and NL(CH040BamHI) 523 
transcription were similarly influenced by IFNγ treatment. Thus, the IFNγ-induced late 524 
block likely occurs posttranscriptionally and CH040 envelope-mediated resistance is not 525 
conferred by enhanced transcription. Importantly, CH040 envelope-mediated resistance 526 
was also recapitulated in primary CD4+ T cells, where NL(CH040BamHI) was also more 527 
resistant to IFNγ than NL4-3 (Figure 7B) or NHG (Figure 1F,G).  528 
Finer mapping using additional chimeric viruses in IFNγ-treated MT4 cells 529 
indicated that resistance was largely determined by a region of CH040 gp120 530 
encompassing amino acids 157 to 448 (Figure 8, Table 2). Importantly, no Rev 531 
responsive sequences or tat/rev coding sequences reside in this region of envelope, 532 
suggesting the underlying mechanism of envelope-mediated IFNγ-resistance is likely 533 
Tat/Rev independent. 534 
 535 
A single amino acid substitution in the HIV-1 envelope can confer substantial 536 
resistance to the IFNγ-induced late block 537 
 As a complementary approach, we simultaneously examined whether IFNγ-538 
resistance might be selected through serial passage in vitro. After 3 passages in IFNγ-539 
treated MT4 cells (P3), HIV-1 appeared to have adapted and replicated far more 540 
efficiently in the presence of IFNγ, with the IFNγ-induced delay in HIV-1 overwhelming 541 
the culture reduced from >1 week to ~1-2 days (Figure 9A). Following passage 5 (P5), 542 
the proviral DNA from the IFNγ-treated cells was PCR-amplified and sequenced. Visual 543 
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inspection of the chromatograms (Figure 9B,C) identified two polymorphisms in vif and 544 
one polymorphism in env that were present in the viral swarm. One synonymous G/A 545 
polymorphism present at G5310 and a single nonsynonymous C/T polymorphism 546 
present at C5387 encoding either serine or leucine at S116 were present in Vif. L116 547 
does not commonly occur in Vif sequences derived from infected patients but serine, 548 
threonine and alanine residues are all common at this site (58). Perhaps more 549 
importantly, of the 3 total polymorphisms that were detected in the swarm propagated in 550 
the presence of IFNγ, only one was selected to uniformity (Figure 9B,C). This single 551 
transition, C6795T, encodes a nonsynonymous substitution in the variable region 2 (V2) 552 
of the envelope glycoprotein (Env), T192M. 553 
To investigate whether the T192M substitution in Env conferred resistance to the 554 
late IFNγ-induced block in MT4 cells, we generated this substitution in isolation within 555 
the parental clone (NHG). HIV-1 T192M had similar replication kinetics to the parental 556 
virus in MT4 cells (Figure 9D). Notably, the T192M virus was partially resistant to IFNγ-557 
mediated inhibition and overran the culture by day 6, when parallel cultures of the 558 
parental virus showed less than 5% infection (Figure 9D). However, position 192 cannot 559 
be the only determinant specifying sensitivity/resistance to the late IFNγ-induced block. 560 
In contrast to NHG, analysis of 5,000 patient sequences (Los Alamos HIV database) 561 
revealed that most HIV-1 env genes encode arginine at this position (~80%) with 562 
isoleucine (~7.5%), threonine (~5.9%) and methionine (4.5%) appearing less 563 
commonly, and valine, lysine, glycine, serine, alanine, and leucine appearing relatively 564 
rarely (<1%). Crucially, both sensitive and resistant variants of HIV-1 encode arginine at 565 
this position (Figure 9E), strongly suggesting other determinant(s) exist within env. 566 
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We next considered the impact of the T192M substitution on a single round of 567 
HIV-1 infection (38). Importantly, the infectious yield of T192M was >10-fold higher than 568 
the yield of the parental virus from IFNγ-treated MT4 cells (Figure 10A-D). At 3 days 569 
postinfection, the yield of T192M was >50-fold higher than the unmodified virus 570 
(although this yield arose from more than one round of infection) (Figure 10B,C). 571 
Interestingly, in contrast to the IFNγ-resistant NL(CH040) chimera (Figure 6,7), the 572 
T192M substitution had little impact on the genesis of progeny virions in IFNγ-treated 573 
cells (Figure 10D, Table 2). The ~10-fold increase in infectious yield (2 day) was 574 
conferred by a marginal <2 fold increase in the abundance of particulate capsid. Thus, 575 
T192M appears to increase the infectiousness of nascent virus particles produced from 576 
IFNγ-treated MT4 cells. 577 
Importantly, replication assays using primary CD4+ T cells indicated that both 578 
T192M and T192R viruses were far more IFNγ-resistant than the parental virus (Figure 579 
10E,F). Not only does this suggest that the molecular details of the block in MT4 cells 580 
are recapitulated in primary cells, but it also highlights the important selection pressure 581 
this block may represent in vivo and underlines the likely importance of residue 192 582 
during HIV-1 transmission. Furthermore, in accordance with our observations using 583 
HIV-1 NL4-3, the late IFNγ-induced block to HIV-1 NHG replication appeared to occur 584 
posttranscriptionally in MT4 cells, as IFNγ treatment inhibited transcription at a similar 585 
magnitude to the weak early block in these cells.  Moreover the T192M substitution did 586 
not enhance transcription in the presence of IFNγ relative to the parental virus (Figure 587 
10G). 588 
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We next examined whether T192M might also confer resistance to type I IFN 589 
treatment in MT4 cells. IFNα2 and IFNγ both induced potent late blocks to HIV-1 590 
production in these cells (Figure 10A-C,H-J). Strikingly, the T192M substitution was able 591 
to confer substantial resistance to IFNα2-induced production inhibition (Figure 10I,J). 592 
Thus, it is possible that type I and type II IFNs inhibit HIV-1 through a common 593 
molecular mechanism in MT4 cells. However, it is also possible that increased particle 594 
infectiousness confers resistance to multiple blocks that are mechanistically distinct. 595 
Importantly, these observations demonstrate that the HIV-1 Env can be a major 596 
determinant in governing sensitivity/resistance to both IFNγ- and IFNα-induced blocks to 597 
HIV-1 replication. Moreover, single amino acid substitutions can substantially alter the 598 
sensitivity to IFN-mediated inhibition. 599 
We finally considered whether the T192M substitution might also confer IFN-600 
resistance in U87 cells, in which type I IFN is known to inhibit HIV-1 infection (12) and in 601 
which HIV-1 is also inhibited with some specificity (Figure 4A). Interestingly, in U87 602 
cells, IFNα2 induces an early block to HIV-1, likely mediated by Mx2 (32) and IFITMs 603 
(30), whereas IFNγ induces a late block (Figure 10K-M). Crucially, the T192M 604 
substitution did not confer the same resistance to the IFN-mediated inhibition of HIV-1 605 
production (Figure 10K-M) that was conferred in MT4 cells and primary CD4+ T cells  606 
(Figure 10A-J). Thus, it is likely that the mechanism of IFNγ-induced late inhibition in 607 
U87 cells is mediated by a mechanism that is distinct from the inhibition in primary 608 
CD4+ T cells and MT4 T cells. 609 
  610 
Discussion 611 
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We have examined the often-overlooked ability of IFNγ to inhibit HIV-1 replication and 612 
have demonstrated that the HIV-1 env gene, including a single amino acid therein, can 613 
determine sensitivity/resistance to IFNγ-mediated inhibition in CD4+ T cells. Importantly, 614 
TF viruses resisted IFNγ inhibition, suggesting that IFNγ-stimulated genes might 615 
constrain HIV-1 transmission. In the process, we have also revealed that VSV-616 
pseudotyping can seemingly confuse the interpretation of specific inhibition phenotypes.  617 
 Unexpectedly, despite efficient Mx2 expression, IFNα2 did not protect THP-1 618 
cells from HIV-1 infection unless the HIV-1 VLPs were decorated with a VSV-G 619 
envelope. Thus, we conclude that IFNα2- or IFNα14-stimulated Mx2 expression is not 620 
sufficient to inhibit HIV-1 (NHG) in THP-1 cells. Crucially, NHG is sensitive to Mx2 621 
inhibition in other contexts (39).  These data are consistent with a recent report which 622 
suggested that endogenous Mx2 cannot inhibit HIV-1 in type I IFN-treated THP-1 cells 623 
(59), but are inconsistent with multiple other studies (32, 33, 60). These previous 624 
studies utilized VSV-pseudotyped HIV-1, and more work (such as the role of type I 625 
interferon subtype or HIV-1 strain) is needed to clarify this apparent discordance.  626 
 Although the route of entry determined IFN inhibition in THP-1 cells, in MT4 cells 627 
IFNγ treatment reduced the genesis of infectious progeny virions (as opposed to 628 
blocking early stage(s) of the HIV-1 lifecycle), regardless of entry route. Nevertheless, 629 
the ability to confer sensitivity/resistance to a post-integration block prior to the 630 
formation of nascent particles unexpectedly resided in the env gene. Although the full 631 
mechanistic basis of this IFN-mediated inhibition and resistance is unclear, there has 632 
been a recent resurgence of interest in Env as a target for antiviral host genes, with 633 
both GBP5 and MARCH8 proposed to inhibit HIV-1 by interfering with the correct 634 
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processing and incorporation of Env glycoproteins (31, 61). Moreover, the TF envelope 635 
defines resistance to an early block caused by IFITM proteins (30). Crucially, GBP5 and 636 
MARCH8 reduce the infectivity of HIV-1 particles as opposed to preventing the genesis 637 
of nascent particles and are thus unable to explain the late block observed here. In 638 
addition, IFITM proteins present an early block (30) or reduce the infectivity of nascent 639 
particles (28, 29) and also cannot explain the late block we have observed here (which 640 
manifests as reduced viral protein expression and attenuated virion biogenesis). 641 
 More work is required to ascertain the relative contribution that particle 642 
infectiousness and efficient viral gene expression might make in conferring the strain-643 
specific IFN-resistance we observe here. Nevertheless, certain patterns regarding 644 
particulate antigen expression are evident. For example, it is clear that for IFNγ- 645 
sensitive viruses (like NHG and NL4-3), at least 90-95% of the large reduction in 646 
infectious yield arises from the reduction in nascent particle production (i.e., the 17-20 647 
fold reduction in VLP p24, Table 2), rather than a loss of infectiousness. Likewise, the 648 
more IFNγ-resistant viruses that include the CH040 envelope, or even just a portion of 649 
CH040 gp120, are better able to sustain particle production in the face of IFNγ 650 
treatment (i.e., only ~3 fold reduction in VLP p24, Table 2). Still, IFNγ-resistant particle 651 
production and increased particle infectiousness are not mutually exclusive and we note 652 
that all of the IFN-resistant viruses we analyzed exhibited relatively minor decreases in 653 
virion-associated gp41 compared to IFN-sensitive viruses (Table 2). In particular, 654 
increased envelope incorporation may explain how the T192M substitution confers 655 
IFNγ-resistance by increasing the infectiousness of individual particles (a ~10-fold gain 656 
in infectivity is conferred by a modest 1-2-fold increase in pelletable p24). It is also 657 
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possible that viruses containing the CH040 envelope retain higher particle infectivity in 658 
the face of IFNγ-treatment (compared to IFN-sensitive viruses). In this regard, TF 659 
viruses are known to more efficiently incorporate viral glycoproteins, and have higher 660 
particle infectivity, than chronic control viruses, highlighting that infectiousness could 661 
impact IFN-resistance (15). Yet the general lack of linearity between infectivity data and 662 
single dose western blot quantification urges caution in the interpretation of smaller 663 
differences in antigen expression, and although we do not rule out the role of particle 664 
infectivity or fusogenicity in CH040 envelope-mediated resistance, the role of particle 665 
production does appear more immediately evident. 666 
Notably, the HIV-1 strains that are sensitive to the late block in MT4 cells are 667 
derived from passaged lab stocks, whereas the resistant viruses are, with one 668 
exception, TF viruses.  The exception is JRCSF, an isolate from the cerebrospinal fluid 669 
of an AIDS patient, which was minimally passaged for 11 days in PBMC prior to 670 
molecular cloning (62). Interestingly, JRCSF has been previously reported to have a 671 
replication profile similar to TF viruses (63). Yet with the relatively small sample of HIV-1 672 
strains tested here we are unable to conclude that only TF viruses resist the late IFN-673 
induced block in MT4 cells. Whether IFN-sensitivity is a property gained through in vitro 674 
passage or whether sensitivity arises in certain chronic virus lineages remains to be 675 
determined.   676 
Likewise, our study has also not yet ruled out that the anti-HIV-1 activity of IFNγ 677 
could be indirect (mediated by an IFNγ-stimulated cytokine). Moreover, whether the 678 
IFNγ-induced inhibition observed in primary cells is phenotypically analogous to the 679 
block in MT4 cells (occurring late in the viral lifecycle) has also not yet been determined.  680 
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However, regardless of the details of the signaling events or inhibitory mechanism 681 
downstream of IFNγ-stimulation, the fact that the envelope of transmitted HIV-1 can 682 
confer remarkable IFN-resistance in primary cells suggests these observations may be 683 
of importance in vivo. 684 
 Interestingly, the same HIV-1 Env residue that was selected during passage in 685 
the presence of IFNγ and conferred IFNγ resistance in primary cells, 192, was recently 686 
identified as a signature site that significantly differed in early versus chronic viruses. 687 
Whilst early viruses were overwhelmingly arginine (R192), this residue was significantly 688 
less represented during chronic infection (64, 65). Clearly residue 192 is not the only 689 
position governing sensitivity/resistance to the late IFN-induced block in MT4 cells, as 690 
both sensitive and resistant viruses encode arginine at this position, and additional 691 
resistance determinant(s) likely reside within env. However, given that the site identified 692 
during in vitro adaptation is apparently enriched during transmission or early infection, it 693 
appears that the factor(s) that mediate the late block described here may influence HIV-694 
1 transmission and/or pathogenesis. Moreover, the observation that all of the TF viruses 695 
largely resisted late IFNγ-mediated inhibition in MT4 cells, while other strains were 696 
robustly (>100-fold) inhibited, suggests that the molecular basis of this block may also 697 
be recapitulated in vivo. 698 
 Strikingly, substitutions at position 192 that conferred resistance to inhibition in 699 
both MT4 and primary CD4+ T cells were also selected during the distinct in vivo 700 
passaging of SHIVs SF162P3 and KU-1 (66, 67) (Figure 9E). These are the only 701 
pathogenic SHIVs we are aware of whose parental env gene did not encode arginine at 702 
this position, and both adapted during passage in vivo. Importantly, this in vivo 703 
 o
n
 January 30, 2017 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jvi.asm.org/
D
ow
nloaded from
 
 32
adaptation took place by infecting macaques for 2 to 16 weeks, a timeframe when IFN 704 
responses and IFN-induced selection are likely most active (1). In accordance with this 705 
idea, Boyd et al, recently reported that adapting pathogenic SHIVs in vivo also selects 706 
for env-mediated IFN-resistance (68). 707 
 We have demonstrated that IFNγ can robustly inhibit HIV-1 in both primary cells 708 
and cell lines, and have shown that the HIV-1 env gene appears to play a key role in 709 
governing the sensitivity/resistance of HIV-1 to IFN-mediated inhibition. The factor(s) 710 
that mediate this block and how transmitted HIV-1 escapes inhibition are currently 711 
unknown. Understanding these events could shed light on the critical and vulnerable 712 
bottleneck that occurs during HIV-1 transmission. 713 
  714 
Acknowledgements 715 
We thank Paul Bieniasz, Andrew Shaw, Trinity Zang, Hans-Georg Kräusslich, Mark 716 
Marsh, Ben Hale, Jim Neil, Greg Towers, Eric O. Freed, Malcolm Martin, Irvin Chen, 717 
Yoshio Koyanagi, Beatrice Hahn, the UK NIBSC, the NIH AIDS Reagent Program and 718 
the Developmental Studies Hybridoma Bank at the University of Iowa for reagents, 719 
viruses and cell lines. We also thank Rob Gifford for his assistance. This study was 720 
supported by MRC awards (MR/K024572/1 and MC_UU_12014/10) to SJW in addition 721 
to Wellcome Trust (WT098049AIA) and ERC awards (281698) to SJDN. 722 
 723 
References 724 
1. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, Lebedeva M, 725 
DeCamp A, Li D, Grove D, Self SG, Borrow P. 2009. Induction of a striking systemic 726 
cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 727 
 o
n
 January 30, 2017 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jvi.asm.org/
D
ow
nloaded from
 
 33
infection, in contrast to more modest and delayed responses in acute hepatitis B and C 728 
virus infections. J Virol 83:3719-3733. 729 
2. Doyle T, Goujon C, Malim MH. 2015. HIV-1 and interferons: who's interfering with 730 
whom? Nat Rev Microbiol 13:403-413. 731 
3. Ho DD, Hartshorn KL, Rota TR, Andrews CA, Kaplan JC, Schooley RT, Hirsch 732 
MS. 1985. Recombinant human interferon alfa-A suppresses HTLV-III replication in 733 
vitro. Lancet 1:602-604. 734 
4. Michaelis B, Levy JA. 1989. HIV replication can be blocked by recombinant human 735 
interferon beta. AIDS 3:27-31. 736 
5. Kornbluth RS, Oh PS, Munis JR, Cleveland PH, Richman DD. 1989. Interferons and 737 
bacterial lipopolysaccharide protect macrophages from productive infection by human 738 
immunodeficiency virus in vitro. J Exp Med 169:1137-1151. 739 
6. Poli G, Orenstein JM, Kinter A, Folks TM, Fauci AS. 1989. Interferon-alpha but not 740 
AZT suppresses HIV expression in chronically infected cell lines. Science 244:575-577. 741 
7. Gendelman HE, Baca LM, Turpin J, Kalter DC, Hansen B, Orenstein JM, 742 
Dieffenbach CW, Friedman RM, Meltzer MS. 1990. Regulation of HIV replication in 743 
infected monocytes by IFN-alpha. Mechanisms for viral restriction. J Immunol 145:2669-744 
2676. 745 
8. Gendelman HE, Baca L, Turpin JA, Kalter DC, Hansen BD, Orenstein JM, 746 
Friedman RM, Meltzer MS. 1990. Restriction of HIV replication in infected T cells and 747 
monocytes by interferon-alpha. AIDS Res Hum Retroviruses 6:1045-1049. 748 
9. Meylan PR, Guatelli JC, Munis JR, Richman DD, Kornbluth RS. 1993. Mechanisms 749 
for the inhibition of HIV replication by interferons-alpha, -beta, and -gamma in primary 750 
human macrophages. Virology 193:138-148. 751 
10. Baca-Regen L, Heinzinger N, Stevenson M, Gendelman HE. 1994. Alpha interferon-752 
induced antiretroviral activities: restriction of viral nucleic acid synthesis and progeny 753 
virion production in human immunodeficiency virus type 1-infected monocytes. J Virol 754 
68:7559-7565. 755 
11. Coccia EM, Krust B, Hovanessian AG. 1994. Specific inhibition of viral protein 756 
synthesis in HIV-infected cells in response to interferon treatment. J Biol Chem 757 
269:23087-23094. 758 
12. Goujon C, Malim MH. 2010. Characterization of the alpha interferon-induced postentry 759 
block to HIV-1 infection in primary human macrophages and T cells. J Virol 84:9254-760 
9266. 761 
13. Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, Chan 762 
ES, Schooley RT, Rinaldo CR, Thielman N, Li XD, Wahl SM, Shore J, Janik J, 763 
Lempicki RA, Simpson Y, Pollard RB, Team ACTGA. 2010. Safety, tolerability, and 764 
mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-765 
monoinfected participants: a phase II clinical trial. J Infect Dis 201:1686-1696. 766 
14. Sandler NG, Bosinger SE, Estes JD, Zhu RT, Tharp GK, Boritz E, Levin D, 767 
Wijeyesinghe S, Makamdop KN, del Prete GQ, Hill BJ, Timmer JK, Reiss E, 768 
Yarden G, Darko S, Contijoch E, Todd JP, Silvestri G, Nason M, Norgren RB, Jr., 769 
Keele BF, Rao S, Langer JA, Lifson JD, Schreiber G, Douek DC. 2014. Type I 770 
interferon responses in rhesus macaques prevent SIV infection and slow disease 771 
progression. Nature 511:601-605. 772 
 o
n
 January 30, 2017 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jvi.asm.org/
D
ow
nloaded from
 
 34
15. Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, Zajic L, Iyer SS, 773 
Decker JM, Kumar A, Hora B, Berg A, Cai F, Hopper J, Denny TN, Ding H, 774 
Ochsenbauer C, Kappes JC, Galimidi RP, West AP, Jr., Bjorkman PJ, Wilen CB, 775 
Doms RW, O'Brien M, Bhardwaj N, Borrow P, Haynes BF, Muldoon M, Theiler JP, 776 
Korber B, Shaw GM, Hahn BH. 2013. Phenotypic properties of transmitted founder 777 
HIV-1. Proc Natl Acad Sci U S A 110:6626-6633. 778 
16. Fenton-May AE, Dibben O, Emmerich T, Ding H, Pfafferott K, Aasa-Chapman 779 
MM, Pellegrino P, Williams I, Cohen MS, Gao F, Shaw GM, Hahn BH, 780 
Ochsenbauer C, Kappes JC, Borrow P. 2013. Relative resistance of HIV-1 founder 781 
viruses to control by interferon-alpha. Retrovirology 10:146. 782 
17. Deymier MJ, Ende Z, Fenton-May AE, Dilernia DA, Kilembe W, Allen SA, Borrow 783 
P, Hunter E. 2015. Heterosexual Transmission of Subtype C HIV-1 Selects Consensus-784 
Like Variants without Increased Replicative Capacity or Interferon-alpha Resistance. 785 
PLoS Pathog 11:e1005154. 786 
18. Fernandez S, Tanaskovic S, Helbig K, Rajasuriar R, Kramski M, Murray JM, 787 
Beard M, Purcell D, Lewin SR, Price P, French MA. 2011. CD4+ T-cell deficiency in 788 
HIV patients responding to antiretroviral therapy is associated with increased expression 789 
of interferon-stimulated genes in CD4+ T cells. J Infect Dis 204:1927-1935. 790 
19. Hardy GA, Sieg S, Rodriguez B, Anthony D, Asaad R, Jiang W, Mudd J, Schacker 791 
T, Funderburg NT, Pilch-Cooper HA, Debernardo R, Rabin RL, Lederman MM, 792 
Harding CV. 2013. Interferon-alpha is the primary plasma type-I IFN in HIV-1 infection 793 
and correlates with immune activation and disease markers. PLoS One 8:e56527. 794 
20. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. 2004. The 795 
cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World 796 
monkeys. Nature 427:848-853. 797 
21. Sayah DM, Sokolskaja E, Berthoux L, Luban J. 2004. Cyclophilin A 798 
retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 799 
430:569-573. 800 
22. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that 801 
inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650. 802 
23. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is 803 
antagonized by HIV-1 Vpu. Nature 451:425-430. 804 
24. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, 805 
Yatim A, Emiliani S, Schwartz O, Benkirane M. 2011. SAMHD1 is the dendritic- and 806 
myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474:654-657. 807 
25. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, 808 
Florens L, Washburn MP, Skowronski J. 2011. Vpx relieves inhibition of HIV-1 809 
infection of macrophages mediated by the SAMHD1 protein. Nature 474:658-661. 810 
26. Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon PM. 2011. Lack of adaptation 811 
to human tetherin in HIV-1 group O and P. Retrovirology 8:78. 812 
27. Armitage AE, Katzourakis A, de Oliveira T, Welch JJ, Belshaw R, Bishop KN, 813 
Kramer B, McMichael AJ, Rambaut A, Iversen AK. 2008. Conserved footprints of 814 
APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human 815 
endogenous retrovirus HERV-K(HML2) sequences. J Virol 82:8743-8761. 816 
 o
n
 January 30, 2017 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jvi.asm.org/
D
ow
nloaded from
 
 35
28. Compton AA, Bruel T, Porrot F, Mallet A, Sachse M, Euvrard M, Liang C, 817 
Casartelli N, Schwartz O. 2014. IFITM proteins incorporated into HIV-1 virions impair 818 
viral fusion and spread. Cell Host Microbe 16:736-747. 819 
29. Tartour K, Appourchaux R, Gaillard J, Nguyen XN, Durand S, Turpin J, 820 
Beaumont E, Roch E, Berger G, Mahieux R, Brand D, Roingeard P, Cimarelli A. 821 
2014. IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint 822 
their infectivity. Retrovirology 11:103. 823 
30. Foster TL, Wilson H, Iyer SS, Coss K, Doores K, Smith S, Kellam P, Finzi A, 824 
Borrow P, Hahn BH, Neil SJ. 2016. Resistance of Transmitted Founder HIV-1 to 825 
IFITM-Mediated Restriction. Cell Host Microbe 20:429-442. 826 
31. Krapp C, Hotter D, Gawanbacht A, McLaren PJ, Kluge SF, Sturzel CM, Mack K, 827 
Reith E, Engelhart S, Ciuffi A, Hornung V, Sauter D, Telenti A, Kirchhoff F. 2016. 828 
Guanylate Binding Protein (GBP) 5 Is an Interferon-Inducible Inhibitor of HIV-1 829 
Infectivity. Cell Host Microbe 19:504-514. 830 
32. Goujon C, Moncorge O, Bauby H, Doyle T, Ward CC, Schaller T, Hue S, Barclay 831 
WS, Schulz R, Malim MH. 2013. Human MX2 is an interferon-induced post-entry 832 
inhibitor of HIV-1 infection. Nature 502:559-562. 833 
33. Kane M, Yadav SS, Bitzegeio J, Kutluay SB, Zang T, Wilson SJ, Schoggins JW, 834 
Rice CM, Yamashita M, Hatziioannou T, Bieniasz PD. 2013. MX2 is an interferon-835 
induced inhibitor of HIV-1 infection. Nature 502:563-566. 836 
34. Cordeil S, Nguyen XN, Berger G, Durand S, Ainouze M, Cimarelli A. 2013. 837 
Evidence for a different susceptibility of primate lentiviruses to type I interferons. J Virol 838 
87:2587-2596. 839 
35. Bitzegeio J, Sampias M, Bieniasz PD, Hatziioannou T. 2013. Adaptation to the 840 
interferon-induced antiviral state by human and simian immunodeficiency viruses. J 841 
Virol 87:3549-3560. 842 
36. Hammer SM, Gillis JM, Groopman JE, Rose RM. 1986. In vitro modification of 843 
human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating 844 
factor and gamma interferon. Proc Natl Acad Sci U S A 83:8734-8738. 845 
37. Koyanagi Y, O'Brien WA, Zhao JQ, Golde DW, Gasson JC, Chen IS. 1988. 846 
Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science 847 
241:1673-1675. 848 
38. Kane M, Zang TM, Rihn SJ, Zhang F, Kueck T, Alim M, Schoggins J, Rice CM, 849 
Wilson SJ, Bieniasz PD. 2016. Identification of Interferon-Stimulated Genes with 850 
Antiretroviral Activity. Cell Host Microbe 20:392-405. 851 
39. Busnadiego I, Kane M, Rihn SJ, Preugschas HF, Hughes J, Blanco-Melo D, 852 
Strouvelle VP, Zang TM, Willett BJ, Boutell C, Bieniasz PD, Wilson SJ. 2014. Host 853 
and viral determinants of Mx2 antiretroviral activity. J Virol 88:7738-7752. 854 
40. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 855 
1986. Production of acquired immunodeficiency syndrome-associated retrovirus in 856 
human and nonhuman cells transfected with an infectious molecular clone. J Virol 857 
59:284-291. 858 
41. Ryan-Graham MA, Peden KW. 1995. Both virus and host components are important 859 
for the manifestation of a Nef- phenotype in HIV-1 and HIV-2. Virology 213:158-168. 860 
42. Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, Wang W, Delaporte E, 861 
Peeters M, Derdeyn CA, Allen S, Hunter E, Saag MS, Hoxie JA, Hahn BH, Kwong 862 
 o
n
 January 30, 2017 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jvi.asm.org/
D
ow
nloaded from
 
 36
PD, Robinson JE, Shaw GM. 2005. Antigenic conservation and immunogenicity of the 863 
HIV coreceptor binding site. J Exp Med 201:1407-1419. 864 
43. Tebit DM, Zekeng L, Kaptue L, Gurtler L, Fackler OT, Keppler OT, Herchenroder 865 
O, Krausslich HG. 2004. Construction and characterization of an HIV-1 group O 866 
infectious molecular clone and analysis of vpr- and nef-negative derivatives. Virology 867 
326:329-339. 868 
44. Zhang YJ, Hatziioannou T, Zang T, Braaten D, Luban J, Goff SP, Bieniasz PD. 869 
2002. Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on 870 
human immunodeficiency virus type 1 attachment and infection. J Virol 76:6332-6343. 871 
45. Wilson SJ, Schoggins JW, Zang T, Kutluay SB, Jouvenet N, Alim MA, Bitzegeio J, 872 
Rice CM, Bieniasz PD. 2012. Inhibition of HIV-1 particle assembly by 2',3'-cyclic-873 
nucleotide 3'-phosphodiesterase. Cell Host Microbe 12:585-597. 874 
46. Cowan S, Hatziioannou T, Cunningham T, Muesing MA, Gottlinger HG, Bieniasz 875 
PD. 2002. Cellular inhibitors with Fv1-like activity restrict human and simian 876 
immunodeficiency virus tropism. Proc Natl Acad Sci U S A 99:11914-11919. 877 
47. Whitt MA. 2010. Generation of VSV pseudotypes using recombinant DeltaG-VSV for 878 
studies on virus entry, identification of entry inhibitors, and immune responses to 879 
vaccines. J Virol Methods 169:365-374. 880 
48. Stratton MR, Reeves BR, Cooper CS. 1989. Misidentified cell. Nature 337:311-312. 881 
49. Rihn SJ, Wilson SJ, Loman NJ, Alim M, Bakker SE, Bhella D, Gifford RJ, Rixon 882 
FJ, Bieniasz PD. 2013. Extreme genetic fragility of the HIV-1 capsid. PLoS Pathog 883 
9:e1003461. 884 
50. Rihn SJ, Hughes J, Wilson SJ, Bieniasz PD. 2015. Uneven genetic robustness of HIV-1 885 
integrase. J Virol 89:552-567. 886 
51. Holmes M, Zhang F, Bieniasz PD. 2015. Single-Cell and Single-Cycle Analysis of 887 
HIV-1 Replication. PLoS Pathog 11:e1004961. 888 
52. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, Dewar RL, 889 
Planta A, Liu S, Metcalf JA, Mellors JW, Coffin JM. 2003. New real-time reverse 890 
transcriptase-initiated PCR assay with single-copy sensitivity for human 891 
immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 41:4531-4536. 892 
53. Harper MS, Guo K, Gibbert K, Lee EJ, Dillon SM, Barrett BS, McCarter MD, 893 
Hasenkrug KJ, Dittmer U, Wilson CC, Santiago ML. 2015. Interferon-alpha Subtypes 894 
in an Ex Vivo Model of Acute HIV-1 Infection: Expression, Potency and Effector 895 
Mechanisms. PLoS Pathog 11:e1005254. 896 
54. Neil S, Bieniasz P. 2009. Human immunodeficiency virus, restriction factors, and 897 
interferon. J Interferon Cytokine Res 29:569-580. 898 
55. Farrar MA, Schreiber RD. 1993. The molecular cell biology of interferon-gamma and 899 
its receptor. Annu Rev Immunol 11:571-611. 900 
56. de Weerd NA, Nguyen T. 2012. The interferons and their receptors--distribution and 901 
regulation. Immunol Cell Biol 90:483-491. 902 
57. Joseph SB, Arrildt KT, Swanstrom AE, Schnell G, Lee B, Hoxie JA, Swanstrom R. 903 
2014. Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide 904 
range of CD4 densities. J Virol 88:1858-1869. 905 
58. Davey NE, Satagopam VP, Santiago-Mozos S, Villacorta-Martin C, Bharat TA, 906 
Schneider R, Briggs JA. 2014. The HIV mutation browser: a resource for human 907 
 o
n
 January 30, 2017 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jvi.asm.org/
D
ow
nloaded from
 
 37
immunodeficiency virus mutagenesis and polymorphism data. PLoS Comput Biol 908 
10:e1003951. 909 
59. Opp S, Vieira DA, Schulte B, Chanda SK, Diaz-Griffero F. 2016. MxB Is Not 910 
Responsible for the Blocking of HIV-1 Infection Observed in Alpha Interferon-Treated 911 
Cells. J Virol 90:3056-3064. 912 
60. Bulli L, Apolonia L, Kutzner J, Pollpeter D, Goujon C, Herold N, Schwarz SM, 913 
Giernat Y, Keppler OT, Malim MH, Schaller T. 2016. Complex interplay between 914 
HIV-1 Capsid and MX2-independent IFNalpha-induced antiviral factors. J Virol 915 
doi:10.1128/JVI.00458-16. 916 
61. Tada T, Zhang Y, Koyama T, Tobiume M, Tsunetsugu-Yokota Y, Yamaoka S, 917 
Fujita H, Tokunaga K. 2015. MARCH8 inhibits HIV-1 infection by reducing virion 918 
incorporation of envelope glycoproteins. Nat Med 21:1502-1507. 919 
62. Cann AJ, Zack JA, Go AS, Arrigo SJ, Koyanagi Y, Green PL, Koyanagi Y, Pang S, 920 
Chen IS. 1990. Human immunodeficiency virus type 1 T-cell tropism is determined by 921 
events prior to provirus formation. J Virol 64:4735-4742. 922 
63. Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, Salazar MG, Salazar-923 
Gonzalez JF, Shattock R, Haynes BF, Shaw GM, Hahn BH, Kappes JC. 2012. 924 
Generation of transmitted/founder HIV-1 infectious molecular clones and 925 
characterization of their replication capacity in CD4 T lymphocytes and monocyte-926 
derived macrophages. J Virol 86:2715-2728. 927 
64. Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, Lapedes AS, 928 
Shen T, Gaschen B, Krishnamoorthy M, Li H, Decker JM, Salazar-Gonzalez JF, 929 
Wang S, Jiang C, Gao F, Swanstrom R, Anderson JA, Ping LH, Cohen MS, 930 
Markowitz M, Goepfert PA, Saag MS, Eron JJ, Hicks CB, Blattner WA, Tomaras 931 
GD, Asmal M, Letvin NL, Gilbert PB, Decamp AC, Magaret CA, Schief WR, Ban 932 
YE, Zhang M, Soderberg KA, Sodroski JG, Haynes BF, Shaw GM, Hahn BH, 933 
Korber B. 2011. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins 934 
associated with either early or chronic infections. PLoS Pathog 7:e1002209. 935 
65. Tully DC, Ogilvie CB, Batorsky RE, Bean DJ, Power KA, Ghebremichael M, 936 
Bedard HE, Gladden AD, Seese AM, Amero MA, Lane K, McGrath G, Bazner SB, 937 
Tinsley J, Lennon NJ, Henn MR, Brumme ZL, Norris PJ, Rosenberg ES, Mayer 938 
KH, Jessen H, Kosakovsky Pond SL, Walker BD, Altfeld M, Carlson JM, Allen TM. 939 
2016. Differences in the Selection Bottleneck between Modes of Sexual Transmission 940 
Influence the Genetic Composition of the HIV-1 Founder Virus. PLoS Pathog 941 
12:e1005619. 942 
66. Hsu M, Ho SH, Balfe P, Gettie A, Harouse J, Blanchard J, Cheng-Mayer C. 2005. A 943 
CCR5-tropic simian-HIV molecular clone capable of inducing AIDS in rhesus macaques. 944 
J Acquir Immune Defic Syndr 40:383-387. 945 
67. Cayabyab M, Karlsson GB, Etemad-Moghadam BA, Hofmann W, Steenbeke T, 946 
Halloran M, Fanton JW, Axthelm MK, Letvin NL, Sodroski JG. 1999. Changes in 947 
human immunodeficiency virus type 1 envelope glycoproteins responsible for the 948 
pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-949 
HXBc2). J Virol 73:976-984. 950 
68. Boyd DF, Sharma A, Humes D, Cheng-Mayer C, Overbaugh J. 2016. Adapting 951 
SHIVs In Vivo Selects for Envelope-Mediated Interferon-alpha Resistance. PLoS Pathog 952 
12:e1005727. 953 
 o
n
 January 30, 2017 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jvi.asm.org/
D
ow
nloaded from
 
 38
69. Collman R, Balliet JW, Gregory SA, Friedman H, Kolson DL, Nathanson N, 954 
Srinivasan A. 1992. An infectious molecular clone of an unusual macrophage-tropic and 955 
highly cytopathic strain of human immunodeficiency virus type 1. J Virol 66:7517-7521. 956 
70. Englund G, Theodore TS, Freed EO, Engelman A, Martin MA. 1995. Integration is 957 
required for productive infection of monocyte-derived macrophages by human 958 
immunodeficiency virus type 1. J Virol 69:3216-3219. 959 
71. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, Decker 960 
JM, Wang S, Baalwa J, Kraus MH, Parrish NF, Shaw KS, Guffey MB, Bar KJ, 961 
Davis KL, Ochsenbauer-Jambor C, Kappes JC, Saag MS, Cohen MS, Mulenga J, 962 
Derdeyn CA, Allen S, Hunter E, Markowitz M, Hraber P, Perelson AS, 963 
Bhattacharya T, Haynes BF, Korber BT, Hahn BH, Shaw GM. 2009. Genetic 964 
identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses 965 
in acute and early HIV-1 infection. J Exp Med 206:1273-1289. 966 
72. Gao F, Yue L, Robertson DL, Hill SC, Hui H, Biggar RJ, Neequaye AE, Whelan 967 
TM, Ho DD, Shaw GM. 1994. Genetic diversity of human immunodeficiency virus type 968 
2: evidence for distinct sequence subtypes with differences in virus biology. Journal of 969 
Virology 68:7433-7447. 970 
 971 
 972 
Figure legends 973 
Figure 1. IFNγ can induce a divergent antiretroviral state and can inhibit HIV-1 in 974 
primary CD4+ T cells. (A-C) THP-1 cells were treated or untreated with 1000 U/ml of 975 
IFNα2 or IFNγ for 24 hours prior to titrated challenge with (A) VSV (VSV-ΔG-GFP.VSV-976 
G), (B) VSV-G pseudotyped, single cycle, HIV-1 (NHGΔenv-GFP+VSV-G) or (C) HIV-1 977 
(NHG). At 18h postinfection cells infected with NHG (C) were treated with dextran 978 
sulfate to limit infection to a single cycle. At 48 hours postinfection, all cells were fixed 979 
and the infectious titer determined using flow cytometry. (D) Mx2 and actin expression 980 
in lysates from IFNα2- or IFNγ-treated cells were assessed using western blotting (WB). 981 
(E) IFN dose responses for IFNα2, IFNα14, and IFNγ were performed as in (C), 982 
including addition of dextran sulfate at 18h postinfection. (F) The infectious HIV-1 (NHG) 983 
yield from human primary CD4+ T cells +/- IFNγ (1 donor, n=4), MOI 0.05, at 3-17 days 984 
(determined by TZM-bl assay). (G) Primary CD4+ T cell replication +/- IFNγ, for 3 985 
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donors, for 3-13 days, MOI 0.05-0.1. Shown are area under the curve (AUC) values 986 
from individual infectious yield growth curves (typical curves shown in (F)). All errors 987 
bars ± SEM. Statistical analyses performed using unpaired (A-C, F) or paired (G) two-988 
tailed t tests (****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns=not significant, p>0.05) 989 
with n=3 to 5. 990 
  991 
 992 
Figure 2. Early blocks to primate lentivirus infection in IFNγ-treated cells are 993 
unusual in cultured human cells.  Human cell lines were treated or untreated with 994 
1000 U/ml of IFNγ for 24 hours prior to titrated challenge with (A) HIV-1 (NHG), (B) 995 
VSV-G pseudotyped HIV-1 (NHGΔenv-GFP) or (C) VSV-G pseudotyped HIV-2 (HIV-996 
2RODΔenv-GFP). Cells infected with NHG (A) were treated with dextran sulfate at 18h 997 
postinfection to limit infection to a single cycle. At 48 hours postinfection, all cells were 998 
fixed and analyzed as in Figure 1A-C.  *ND=not detectable. All error bars ± SEM, n=3 to 999 
5. 1000 
 1001 
 1002 
Figure 3. Multiple human cell lines exhibit late IFNγ-induced blocks to HIV 1003 
replication. (A, C) A panel of human cell lines were pretreated (or untreated) with 1000 1004 
U/ml of IFNγ for 24 hours prior to challenge with NHG (denoted by * in A and B), VSV-G 1005 
pseudotyped NHG (A and B) or VSV-G pseudotyped ROD10 (C). For cells in which the 1006 
incoming block (Fig 2B,C) was ≥2.5 fold (A549 (HIV-1 and HIV-2), TZM-bl (HIV-1) and 1007 
U87 (HIV-1) cells), the weak incoming blocks were accounted for by increasing the 1008 
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inoculum in proportion to the strength of the incoming block (+IFNγ (norm), although this 1009 
was not achievable in THP-1 cells (excessive virus volume). The infectious yield was 1010 
determined 46-48 hours postinfection through titration of the harvested cell-free virus-1011 
containing supernatant onto either MT4 cells (A) or TZM-bl cells (C). (B) HIV-1 1012 
particulate capsid abundance (p24) in the supernatant (VLPs), as well as cellular Gag 1013 
(Pr55), capsid (p24), phosphorylated STAT1 and host actin expression in the HIV-1 1014 
producer cells (A) were monitored by western blotting. All error bars ± SEM, n=3 to 5. 1015 
  1016 
 1017 
Figure 4. MT4 cells display an HIV-1 specific block that is independent of both 1018 
route of viral entry and IDO1. (A) Cell line protection from infection (blue circles, using 1019 
NHGΔenv-GFP and HIV-2RODΔenv-GFP) or the reduction in infectious yield (maroon 1020 
circles) for HIV-1 and HIV-2 using data from Figures 2 and 3. (B) The infectious yield of 1021 
HIV-1 (NHG) from MT4 cells pretreated with varying doses (0-1000 U/ml) of IFNγ was 1022 
quantified as in Figure 3A. (C) Viral antigens present in particulate material or cell 1023 
lysates were measured by western blot, using the samples from (B). (D, E) The 1024 
infectious yield of IFNγ pretreated (1000 U/ml) or untreated MT4 cells resulting from 1025 
either HIV-1 (D) or HIV-2 (E) infection at various multiplicities, and in the presence or 1026 
absence of VSV-G pseudotyping, was determined through titration of the harvested 1027 
indicated virus on TZM-bl indicator cells as in Figure 3C. (F) IDO1 expression was 1028 
monitored in MT4 cells +/- IFNγ via western blot. (G) The fold-increase in the yield of 1029 
infectious HIV-1 from IFNγ-pretreated MT4 (NHG) or A549 (VSV-G pseudotyped NHG) 1030 
cells in the presence of 50 μg/ml exogenous L-tryptophan (L-Trp) or 100 μg/ml of the 1031 
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IDO1 competitive inhibitor 1-methyl-L-tryptophan (1MT) was determined as in (B). All 1032 
errors bars ± SEM. Statistical analyses performed using unpaired, two-tailed t tests, n=3 1033 
to 5 (****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns=not significant, p>0.05).  1034 
  1035 
 1036 
Figure 5. The late IFNγ-induced block in MT4 cells is HIV-1 strain-specific. (A) 1037 
CCR5+ MT4-LTR-GFP (MT4-R5-LTR-GFP) indicator cells were pretreated (24h) or 1038 
untreated with 1000 U/ml of IFNγ prior to titrated challenge with a panel of HIV-1 1039 
infectious molecular clones with and without VSV-G pseudotyping. (B) The infectious 1040 
yield of HIV-1 (pseudotyped and non-pseudotyped, as indicated) produced from MT4-1041 
R5-LTR-GFP cells +/- IFNγ pretreatment was determined through titration of the 1042 
indicated progeny virus (harvested at 46-48 h postinfection) on TZM-bl indicator cells. 1043 
(C) To quantify the IFNγ-mediated block to HIV-1 infectious virus production whilst 1044 
taking into account weak early blocks to infection, the mean fold reduction or inhibition 1045 
in production (normalized fold reduction) was calculated by dividing the mean reduction 1046 
in infectious yield (fold change determined in B) for each virus by the mean protection 1047 
from infection (fold change determined in A) for that virus. (D-F) Representations of the 1048 
incoming (D), infectious yield (E) and production inhibition (F) IFNγ-mediated effects 1049 
between HIV-1 lab strain and TF viruses, using the data from (A-C). Designations of TF 1050 
(vs lab strain) viruses can be found in Table 1. In (A-C), +G is used to denote the 1051 
viruses which have been VSV-G pseudotyped.  Viruses denoted by *ND are those in 1052 
which we were unable to measure the infectious yield as the incoming infectious titer 1053 
was too low (without VSV-G pseudotyping), correspondingly *NM=not measurable (due 1054 
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to not detectable portion of calculation). Error bars ± SEM (n=3 to 5), statistical analyses 1055 
in (D-F) use Mann-Whitney tests (****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns=not 1056 
significant, p>0.05).    1057 
 1058 
 1059 
Figure 6. Sensitivity/resistance to the late IFNγ-induced block in MT4 cells maps 1060 
to the env gene. (A) Representations of the chimeric and parental infectious* molecular 1061 
clones of NL4-3 and CH040 used in (B-E). The restriction sites used to clone the 1062 
chimeras are shown. (B) The incoming titer, (C) the yield of infectious progeny, (D) the 1063 
mean fold reduction in infectious HIV-1 production (calculated as in Figure 5) and (E) 1064 
the particulate supernatant capsid and cellular Gag/capsid, gp160, and phosphorylated 1065 
STAT1 expression were assessed using MT4-R5-LTR-GFP cells in the 1066 
presence/absence of IFNγ pretreatment (as well as VSV-G), as described in Figures 4 1067 
and 5. The western blots shown in (E) are those from the VSV-G pseudotyped 1068 
infections to ensure readily measurable Gag expression. *pNL-040-BA was reproducibly 1069 
severely attenuated and we were unable to detect infection/replication using this clone. 1070 
Error bars ± SEM (n=3 to 5). 1071 
  1072 
 1073 
Figure 7. The late IFNγ-induced inhibition occurs posttranscriptionally and is 1074 
recapitulated in primary CD4+ T cells in a manner rescued by CH040 env. (A) The 1075 
number of copies of transcribed gag (following subtraction of cell-associated viral RNA, 1076 
all measured by qPCR) in the presence or absence of reverse transcriptase (RT) for 1077 
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NL4-3 and NL(CH040BamHI), either with or without IFNγ pretreatment (24h) in MT4-R5-1078 
LTR-GFP cells. (B) Infectious yield of NL4-3 and NL(CH040BamHI) from primary CD4+ T 1079 
cells, +/- IFNγ, at 3-17 days, MOI 0.1 (Donor A) or 0.05 (Donor B). Yield determined by 1080 
TZM-bl assay (n=4 per donor). The IFNγ sensitivity of Donor B to lab strain HIV-1 is 1081 
shown in Figure 1G.  All error bars ± SEM. 1082 
 1083 
 1084 
Figure 8. Sensitivity/resistance to the late IFNγ-induced block in MT4 cells maps 1085 
to regions of env preceding V5. (A) Representations of the env chimeric and parental 1086 
infectious* molecular clones of NL4-3 and CH040 used in (B-E), with portions of NL4-3 1087 
shown in black and portions of CH040 in maroon. Portions of the chimeric clones not 1088 
shown are derived from NL4-3. (B) The incoming titer, (C) the yield of infectious 1089 
progeny, (D) the mean fold reduction in infectious HIV-1 production (calculated as in 1090 
Figure 5), and (E) the particulate supernatant capsid and gp41 and cellular Gag/capsid 1091 
and gp160 were assessed using MT4-R5-LTR-GFP cells in the presence/absence of 1092 
IFNγ pretreatment (as well as VSV-G), as described in Figure 6. The western blots 1093 
shown in (E) are those from the VSV-G pseudotyped infections to ensure readily 1094 
measurable Gag expression. pNL(CH0401-381) appeared to be reproducibly unable to 1095 
produce infectious particles, as no infectious particles were detected in the infectious 1096 
yield assay, and no incoming titer could be detected in the absence of VSV-G. *ND=not 1097 
detectable, *NM=not measurable (due to not detectable portion of calculation), *Min 1098 
(minimum possible amount of inhibition due to not detectable portion of calculation). All 1099 
error bars ± SEM (n=3 to 5). 1100 
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  1101 
 1102 
Figure 9. Single substitutions in the HIV-1 envelope can substantially alter 1103 
susceptibility to the late IFNγ-induced block in MT4 cells. (A) MT4 cells with and 1104 
without pretreatment with 1000 U/ml of IFNγ were infected with MOI ~0.001 HIV-1 1105 
(NHG). The percentage of GFP+ cells over time is shown (determined using flow 1106 
cytometry). HIV-1 propagated in the presence of IFNγ was used to inoculate fresh MT4 1107 
cells (at the times indicated with arrows) +/- IFNγ pretreatment. (B, C) Sanger 1108 
sequencing chromatograms from PCR-amplified proviral DNA from the parental clone or 1109 
the P5 swarm from vif (B) or env (C) are shown (SNPs highlighted with arrows). (D) 1110 
Replication of the T192M mutant and the parental clone was measured as in (A). (E) An 1111 
amino acid alignment of the V2 region of gp120 of the 4 most IFNγ-sensitive and 1112 
resistant strains from Figure 5, along with two pathogenic SHIVs (SF162P3 and KU-1) 1113 
and the corresponding HIV-1 envelope sequence (SF162 and HXB2 respectively). T192 1114 
(NHG) is indicated with an arrow and coloured shading.  1115 
  1116 
 1117 
Figure 10. T192M confers partial resistance to late IFNα2- and IFNγ-mediated 1118 
inhibition in MT4 and primary CD4+ T cells, but not in U87 cells.  (A) The infectious 1119 
titer and (B) infectious yield in the presence and absence of IFNγ pretreatment, as well 1120 
as (C) production inhibition were assessed for HIV-1 (NHG) and the T192M mutant in 1121 
MT4 cells, as described in Figure 5 (although the virus-containing supernatants used to 1122 
calculate the infectious yield (B) were titrated on MT4 cells rather than TZM-bl cells, as 1123 
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in Figure 3A). (D) Viral capsid and glycoprotein abundance in cell lysates and 1124 
supernatant particulate matter from (B) (day 2) was assessed by western blotting. (E) 1125 
Infectious yield of NHG, NHG T192M and NHG T192R from primary CD4+ T cells, +/- 1126 
IFNγ, MOI 0.05, at 3-17 days (determined by TZM-bl assay, shown are average values 1127 
from 2 donors, n=4 per donor). (F) Primary CD4+ T cell sensitivity to IFNγ, as 1128 
determined by ratios of the areas under the curve (AUC) analyses (–IFNγ AUC / +IFNγ 1129 
AUC), using data from (E). (G) The number of copies of transcribed gag (following 1130 
subtraction of cell-associated viral RNA, all measured by qPCR), in the presence or 1131 
absence of reverse transcriptase (RT) for NHG and NHG T192M, either with or without 1132 
IFNγ pretreatment (24h), as indicated, in MT4 cells. (H-J) The impact of IFNα2 1133 
pretreatment (24 h) was assessed as in (A-C) in MT4 cells. (K-M) The impact of IFNγ 1134 
and IFNα2 in U87 cells was assessed as in (A-C), but using VSV-G pseudotyped NHG 1135 
and T192M. All error bars ± SEM, n=3 to 5, statistical analyses performed using 1136 
unpaired two-tailed t tests (****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns=not 1137 
significant, p>0.05). 1138 
  1139 
 1140 
  1141 
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 1142 
Table 1. Viruses used in this study 
Virus (subtype) Designation Notes (a plasmid 
catalog number) 
Accession TF Coreceptor 
Tropism 
Reference 
HIV-1 (B) NHG GFP in place of nef JQ585717 No X4 (45) (44) 
HIV-1 (B) NHGΔenv-GFP Lacks a functional env 
gene, GFP in place  
of nef 
N/A No N/A (44) (46) 
HIV-1 (B) NL4-3 (114) M19921.2 No X4 (40) 
HIV-1 (B) 89.6 (3552) U39362 No R5/X4 (69) 
HIV-1 (B) NL(AD8) (11346) N/A No R5 (70) 
HIV-1 (B) JRCSF (2708)  M38429 No R5 (62) 
       
HIV-1 (B) RHPA (11744) JN944944 Yes R5 (63) 
       
HIV-1 (B) CH106 (11743) JN944942 Yes R5 (63) 
HIV-1 (B) REJO (11746) JN944943 Yes R5 (63) 
HIV-1 (B) WITO (11739) JN944948 Yes R5 (63) 
HIV-1 (C) ZM249M-1 (12260) Noteb Yes R5 (15, 71) 
HIV-1 (B) CH077 (11742) JN944941 Yes R5/X4 (63) 
HIV-1 (B) THRO (11745) JN944946 Yes R5 (63) 
HIV-1 (B) CH058 (11856) JN944940 Yes R5 (63) 
HIV-1 (B) CH040 (11740) JN944939 Yes R5 (63) 
       
HIV-1 Group O CMO2.5  AY623602.1 No (43) 
HIV-2 HIV-2RODΔenv-
GFP 
Lacks a functional env 
gene, GFP in place  
of nef 
N/A No N/A (33) 
HIV-2 ROD10  M15390, 
KY272752 
No  (41) 
HIV-2 7312A  L36874 No R5 (72) 
a NIH AIDS Reagent Program catalogue number  1143 
b Sequence available from the NIH AIDS Reagent Program  1144 
 1145 
 1146 
 1147 
 1148 
 1149 
 1150 
 1151 
 1152 
 1153 
 1154 
 1155 
 1156 
 1157 
 1158 
 1159 
 1160 
 1161 
 1162 
 1163 
 1164 
 1165 
 1166 
 1167 
 1168 
 1169 
 1170 
 1171 
 1172 
 1173 
 1174 
 1175 
 1176 
 1177 
 1178 
 1179 
 1180 
 1181 
 o
n
 January 30, 2017 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jvi.asm.org/
D
ow
nloaded from
 
 47
 1182 
Table 2. Characterization of IFNγ-induced changes in nascent  1183 
particles of sensitive and resistant viruses a 1184 
Virus 
Particulate 
p24 
reduction 
(fold) b 
Particulate 
gp41 
reduction 
(fold) c 
Relative 
change in Env 
per particle d 
NHG* 20.7 25.3 0.8 
NHG T192M 9.4 6.4 1.5 
NL4-3* 17.0 20.7 0.8 
CH040 3.2 2.0 1.6 
NL(CH0401-502) 2.9 1.4 2.1 
 1185 
a IFNγ-induced reductions in antigen expression as measured by  1186 
LI-COR quantitative western blotting (typical blots shown in Figures 4-10). 1187 
b IFNγ-induced reduction in particulate (VLP) p24  1188 
(fold change of VLP –IFNγ p24 / +IFNγ p24). 1189 
c IFNγ-induced reduction in particulate (VLP) gp41 (fold change of  1190 
VLP –IFNγ gp41 / +IFNγ gp41). 1191 
d Ratio of the IFNγ-induced reduction in particulate p24 b to the  1192 
reduction in gp41 c.  A value <1 suggests that there is less gp41 per  1193 
particle following IFNγ treatment. 1194 
*Shown is mean fold change calculated from multiple experiments. 1195 
 1196 
 1197 
 1198 
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